Back to top Open menu arrow
Download PDF Reprints

The Journal of
Clinical Psychiatry
Members only

Original Research February 18, 2026

The Effects of Extended Cannabis Abstinence in Comorbid Posttraumatic Stress Disorder and Cannabis Use Disorder

; ; ; ;

J Clin Psychiatry 2026;87(1):25m16099

Abstract

Objective: This preliminary open-label study examined whether 12 weeks of cannabis abstinence was associated with posttraumatic stress disorder (PTSD) symptom improvement in people with comorbid PTSD and cannabis use disorder (CUD) (N=21).

Methods: Participants received progressive contingency reinforcement payments for successful abstinence at weeks 4, 8, and 12. Abstinence was defined as a 11-nor-9-carboxy-tetrahydrocannabinol (THC-COOH) level ≤50 ng/mL with no self-reported cannabis use. PTSD symptoms were evaluated using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), capturing total severity, symptom count, and cluster scores. Data were collected from January 2022 to April 2025.

Results: Participants who achieved abstinence (n=11) reported significantly greater reductions in total PTSD symptom severity and symptom count relative to those who did not (n=10). CAPS-5 total scores decreased from 36.2 to 10.5 among abstainers versus 34.6 to 21.8 among nonabstainers (P=.001). Time-by-group interactions revealed more pronounced improvements in avoidance, negative mood and cognition, and hyperarousal among abstainers. Reexperiencing symptoms improved across both groups over time, with no significant difference by abstinence status.

Conclusions: Sustained cannabis abstinence was associated with significant reductions in PTSD symptom severity and frequency over 12 weeks. While not definitive, the results raise questions about the assumption that long-term cannabis use improves symptoms or functioning in PTSD. The data instead suggest that continued cannabis use could limit recovery in some domains. This underscores the need to routinely assess cannabis use during PTSD treatment and to educate patients on the potential consequences of continued use. Larger randomized trials are warranted to replicate and extend these findings and to investigate mechanisms through which abstinence may relate to symptom changes in PTSD with CUD.

Trial Registration: ClinicalTrials.gov identifier: NCT05162651.

J Clin Psychiatry 2026;87(1):25m16099

Author affiliations are listed at the end of this article.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Mann SK, Marwaha R, Torrico TJ. Posttraumatic stress disorder. In: StatPearls. StatPearls Publishing; 2025.
  2. Fox V, Dalman C, Dal H, et al. Suicide risk in people with post-traumatic stress disorder: a cohort study of 3.1 million people in Sweden. J Affect Disord. 2021;279:609–616. PubMed CrossRef
  3. Hicks EM, Niarchou M, Goleva S, et al. Comorbidity profiles of posttraumatic stress disorder across the medical phenome. Biol Psychiatry Glob Open Sci. 2024;4(5):100337. PubMed CrossRef
  4. Levin Y, Lev Bar-Or R, Forer R, et al. The association between type of trauma, level of exposure and addiction. Addict Behav. 2021;118:106889. PubMed CrossRef
  5. Blume AW, Schmaling KB, Marlatt GA. Revisiting the self-medication hypothesis from a behavioral perspective. Cognitive Behav Pract. 2000;7(4):379–384. CrossRef
  6. Lake S, Kerr T, Buxton J, et al. Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? Evidence from a population-based cross-sectional study of Canadians. J Psychopharmacol. 2020;34(2):181–188. PubMed CrossRef
  7. Bilevicius E, Sommer JL, Asmundson GJG, et al. Associations of PTSD, chronic pain, and their comorbidity on cannabis use disorder: results from an American nationally representative study. Depress Anxiety. 2019;36(11):1036–1046. PubMed CrossRef
  8. Livingston NA, Farmer SL, Mahoney CT, et al. Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. Psychol Addict Behav. 2022;36(2):131–143. PubMed CrossRef
  9. Peters EN, Schwartz RP, Wang S, et al. Psychiatric, psychosocial, and physical health correlates of co-occurring cannabis use disorders and nicotine dependence. Drug Alcohol Depend. 2014;134:228–234. PubMed CrossRef
  10. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559–564. PubMed CrossRef
  11. Bonn-Miller MO, Brunstetter M, Simonian A, et al. The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder. Cannabis Cannabinoid Res. 2022;7(2):214–223. PubMed CrossRef
  12. Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–588. PubMed CrossRef
  13. Zabik NL, Iadipaolo A, Peters CA, et al. Dose-dependent effect of acute THC on extinction memory recall and fear renewal: a randomized, double-blind, placebo-controlled study. Psychopharmacol Berl. 2024;16.
  14. Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry. 2015;76(09):1174–1180. PubMed CrossRef
  15. Bedard-Gilligan M, Garcia N, Zoellner LA, et al. Alcohol, cannabis, and other drug use: engagement and outcome in PTSD treatment. Psychol Addict Behav. 2018;32(3):277–288. PubMed CrossRef
  16. Rodas JD, George TP, Hassan AN. A systematic review of the clinical effects of cannabis and cannabinoids in posttraumatic stress disorder symptoms and symptom clusters. J Clin Psychiatry. 2024;85(1):23r14862. PubMed CrossRef
  17. Veterans for Medical Cannabis Access. Information for Patients. VMCA. Accessed October 18, 2025. http://veteransformedicalmarijuana.org/content/information-patients
  18. Veterans Affairs Canada. CMP Expenditures, Clients And Grams Reimbursed 2014-2020. Veterans Affairs Canada; 2021. Accessed October 18, 2025. https://cdn.cloud.veterans.gc.ca/pdf/about-vac/publications-reports/reports/cannabis-medical-purposes-data-2014-2020.pdf
  19. Veterans Affairs Canada (VAC), Research Directorate. Cannabis for Medical Purposes. Veterans Affairs Canada; 2022.
  20. Grant S, Pedersen ER, Neighbors C. Associations of posttraumatic stress disorder symptoms with marijuana and synthetic cannabis use among young adult U.S. veterans: a pilot investigation. J Stud Alcohol Drugs. 2016;77(3):509–514. PubMed CrossRef
  21. Bonn-Miller MO, Brunstetter M, Simonian A, et al. The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder. Cannabis Cannabinoid Res. 2022;7(2):214–223. PubMed CrossRef
  22. Rotermann M. Analysis of trends in the prevalence of cannabis use and related metrics in Canada. Health Rep. 2019;30(6):3–13. PubMed CrossRef
  23. Wang Q, Qin Z, Xing X, et al. Prevalence of cannabis use around the world: a systematic review and meta-analysis, 2000-2024. China CDC Wkly. 2024;6(25):597–604. PubMed CrossRef
  24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5-TR. American Psychiatric Association Publishing; 2022.
  25. First MB, Williams JBW, Karg RS, et al. Structured Clinical Interview for DSM-5 Disorders: Research Version (SCID-5-RV). American Psychiatric Association; 2015.
  26. Weathers FW, Blake DD, Schnurr PP, et al. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) – Past Month. National Center for PTSD; 2015. Accessed October 30, 2025. https://www.ptsd.va.gov/
  27. PharmaDrugTest. Cannabis THC Test Levels in Urine. PharmaDrugTest. Accessed July 8, 2025. https://www.pharmadrugtest.com/urine-drug-tests/42-cannabis-thc-test-levels-urine.html
  28. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
  29. Ware JJr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–233. PubMed CrossRef
  30. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Humana Press;1992:41–72. CrossRef
  31. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–897. PubMed CrossRef
  32. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561–571. PubMed CrossRef
  33. Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test–Revised (CUDIT-R). Drug Alcohol Depend. 2010;110(1-2):137–143. PubMed CrossRef
  34. Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94(9):1311–1322. PubMed CrossRef
  35. Goodwin RS, Darwin WD, Chiang CN, et al. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol. 2008;32(8):562–569. PubMed CrossRef
  36. Rabin RA, Kozak K, Zakzanis KK, et al. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls. Schizophr Res. 2018;194:47–54. PubMed CrossRef
  37. Bonn-Miller MO, Boden MT, Vujanovic AA, et al. Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder symptoms among veterans in residential treatment. Psychol Trauma Theor Res Pract Pol. 2013;5(2):193–200. CrossRef
  38. Manhapra A, Stefanovics E, Rosenheck R. Treatment outcomes for veterans with PTSD and substance use: impact of specific substances and achievement of abstinence. Drug Alcohol Depend. 2015;156:70–77. PubMed CrossRef
  39. Earleywine M, Bolles JR. Marijuana, expectancies, and post-traumatic stress symptoms: a preliminary investigation. J Psychoactive Drugs. 2014;46(3):171–177. PubMed CrossRef
  40. Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162–165. PubMed CrossRef
  41. Buckner JD, Jeffries ER, Crosby RD, et al. The impact of PTSD clusters on cannabis use in a racially diverse trauma-exposed sample: an analysis from ecological momentary assessment. Am J Drug Alcohol Abuse. 2018;44(5):532–542. PubMed CrossRef
  42. Bedard-Gilligan M, Lehinger E, Cornell-Maier S, et al. Effects of cannabis on PTSD recovery: review of the literature and clinical insights. Curr Addict Rep. 2022;9(3):203–216. PubMed CrossRef
  43. Burggren AC, Shirazi A, Ginder N, et al. Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives. The Am J Drug Alcohol Abuse. 2019;45(6):563–579. PubMed CrossRef
  44. Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci. 2015;16(10):579–594. PubMed CrossRef
  45. D’Souza DC, Cortes-Briones JA, Ranganathan M, et al. Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1(1):60–67. CrossRef
  46. Buckner JD, Walukevich Dienst K, Zvolensky MJ. Distress tolerance and cannabis craving: the impact of laboratory-induced distress. Exp Clin Psychopharmacol. 2019;27(1):38–44. PubMed CrossRef
  47. Connor JP, Stjepanović D, Le Foll B, et al. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7(1):16. PubMed CrossRef
  48. Vøllestad J, Nielsen MB, Nielsen GH. Mindfulness-and acceptance-based interventions for anxiety disorders: a systematic review and meta-analysis. Br J Clin Psychol. 2012;51(3):239–260. PubMed
  49. Boyd JE, Lanius RA, McKinnon MC. Mindfulness-based treatments for posttraumatic stress disorder: a review of the treatment literature and neurobiological evidence. J Psychiatry Neurosci. 2018;43(1):7–25. PubMed CrossRef
  50. Rowe-Johnson MK, Browning B, Scott B. Effects of acceptance and commitment therapy on trauma-related symptoms: a systematic review and meta-analysis. Psychol Trauma Theor Res Pract Pol. 2025;17(3):668–675. PubMed CrossRef
  51. Papini S, Ruglass LM, Lopez-Castro T, et al. Chronic cannabis use is associated with impaired fear extinction in humans. J Abnorm Psychol. 2017;126(1):117–124. PubMed CrossRef
  52. Viveros M, Marco E, File S. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav. 2005;81(2):331–342. PubMed CrossRef
  53. Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial. In: Le Foll B, ed. .PLoS ONE. 2021;16(3):e0246990. CrossRef
  54. Boden MT, Babson KA, Vujanovic AA, et al. Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict. 2013;22(3):277–284. PubMed CrossRef
  55. Passie T, Emrich HM, Karst M, et al. Mitigation of post-traumatic stress symptoms by cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Analysis. 2012;4(7-8):649–659. PubMed CrossRef

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

Figure. Journal cover highlights articles on bipolar II depression therapy, schizophrenia treatment, and adult ADHD symptoms.

Vol 86 • 2025 • Number 4

Read the Current Issue

Original Research

Effects of Interpersonal and Social Rhythm Therapy on Suicidal Ideation in Adults with Bipolar II Depression

Academic Highlights

Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report

Academic Highlights

Psychosocial Interventions and Functional Recovery in Schizophrenia

Original Research

Symptom Network Analysis of ADHD and Emotional Symptoms in Adults

Original Research

Emory Treatment Resistance Interview for PTSD—Short Version

Original Research

Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder
View current Issue

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe